Biodesix, Inc. (BDSX) is a Healthcare stock trading at $27.87 (as of 2026-08-25), with a market capitalization of $294.06M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Biodesix, Inc. provides blood-based diagnostic testing focused on lung cancer risk assessment and molecular characterization, including Nodify XL2 and Nodify CDT, as well as GeneStrat ddPCR and VeriStrat, and a 72-hour GeneStrat NGS test. It also offers COVID-19 testing through its WorkSafe program with Bio-Rad, and provides diagnostic and clinical research and clinical trial testing services.
Understand Biodesix, Inc.: how it makes money
Biodesix sells blood-based biomarker tests (Nodify, GeneStrat, VeriStrat) to physicians to assess lung nodule malignancy risk and identify cancer mutations, charging per test. Revenue is almost entirely from diagnostic test volume ordered in primary and specialty care, with a smaller development-services line to biopharma partners.
Every revenue dollar is one test in a patient's hand, so the entire growth thesis hinges on销售-rep-driven test volume scaling faster than the fixed cost base.
Revenue by segment (latest quarter)
Lung Diagnostic Tests
$0.0B
Development Services
$0.0B
Business quality (Weak): Weak: the company burns cash (operating margin -20%) on a revenue base of roughly $20 million, and profitability remains years out at current scale.
Bull case
Contracted revenue de-risks 2026: Management cited $11.8 million of contracted business entering 2026, giving investors a near-term revenue floor against a ~$20 million run-rate. That visibility is rare for a company this size and caps downside on the growth story.
Guided growth outpaces the base: FY26 guidance at the midpoint implies 23% revenue growth on a small base, and the sales force is expanding by roughly six representatives per quarter. If test volumes keep compounding at 60% YoY, the operating-leverage inflection comes sooner than a static model would suggest.
Partnerships open a second revenue leg: The Thermo Fisher and Bio-Rad agreements convert Biodesix's assay IP into development-services fees from large pharma and CRO customers, diversifying revenue beyond per-test diagnostics without proportional headcount cost.
Bear case
Cash burn outpaces revenue scale: Operating margin sat at -20% for the period, and management confirmed the company remained unprofitable for the full year. With revenue near $20 million, every additional sales rep and lab capacity adds to the loss until volumes clear the break-even threshold, which has not yet been reached.
Seasonality creates optics risk: First-quarter test volume and average selling price typically decline due to seasonal effects, and weather disruption plus prior-period collection timing can make Q1 comparisons look worse than the underlying trend. Investors who react to a soft Q1 print may sell into a cyclical dip rather than a fundamental break.
No near-term product catalyst: Management stated pipeline tests will not be commercialized within the next 12 months, meaning the next product-driven revenue inflection is at least two quarters away. The entire 2026 story rests on existing-test volume growth and the development-services line, leaving no new-product tailwind to offset any stalling in lung-test demand.